Literature DB >> 1885797

FDG-PET in the selection of brain lesions for biopsy.

M W Hanson1, M J Glantz, J M Hoffman, A H Friedman, P C Burger, S C Schold, R E Coleman.   

Abstract

The CT-guided stereotaxic needle biopsy has become a widely used procedure in the diagnostic evaluation of intracranial lesions including tumors. Conventional CT or MR frequently defines the anatomic regions of abnormality, which may be multiple lesions or a single lesion that is heterogeneous in cellular composition owing to the topographic variation of cellular constituency or the combination of active disease, nonspecific inflammation, necrosis, and/or edema. In these cases, selection of the most appropriate site for a successful diagnostic needle biopsy can be difficult. In three patients, we have used [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) to determine the site most likely to provide a diagnostic biopsy result. In the first patient, who presented with confusion, multiple biopsies from the temporal lobe, based on MR abnormalities, revealed only reactive gliosis and edema. Repeat biopsy directed by PET revealed an anaplastic astrocytoma. In a second patient, PET allowed us to differentiate radiation effect from active metastatic breast cancer. In the third patient, who presented with a grand mal seizure, biopsy of a CT-defined hypodense region demonstrated lymphocytosis. Metabolism of FDG was normal or increased in areas of Aspergillus encephalitis at autopsy. These preliminary studies suggest a complementary role for FDG-PET and CT or MR in selected patients for defining the intracranial site most likely to yield a positive biopsy result.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1885797     DOI: 10.1097/00004728-199109000-00013

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  13 in total

Review 1.  Positron emission tomography and the central nervous system.

Authors:  R O Robinson; C D Ferrie; M Capra; M N Maisey
Journal:  Arch Dis Child       Date:  1999-09       Impact factor: 3.791

2.  FDG-PET in infectious lesions: The detection and assessment of lesion activity.

Authors:  Y Ichiya; Y Kuwabara; M Sasaki; T Yoshida; Y Akashi; S Murayama; K Nakamura; T Fukumura; K Masuda
Journal:  Ann Nucl Med       Date:  1996-05       Impact factor: 2.668

Review 3.  PET Molecular Imaging-Directed Biopsy: A Review.

Authors:  Baowei Fei; David M Schuster
Journal:  AJR Am J Roentgenol       Date:  2017-05-15       Impact factor: 3.959

Review 4.  Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.

Authors:  P Rigo; P Paulus; B J Kaschten; R Hustinx; T Bury; G Jerusalem; T Benoit; J Foidart-Willems
Journal:  Eur J Nucl Med       Date:  1996-12

5.  Intracranial aspergillosis involving the internal auditory canal and inner ear in an immunocompetent patient.

Authors:  Y-S Cho; D K Lee; S D Hong; W S Oh
Journal:  AJNR Am J Neuroradiol       Date:  2007-01       Impact factor: 3.825

Review 6.  Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology?

Authors:  C S Brock; S R Meikle; P Price
Journal:  Eur J Nucl Med       Date:  1997-06

Review 7.  Targeted imaging and therapy of brain cancer using theranostic nanoparticles.

Authors:  Mahaveer Swaroop Bhojani; Marcian Van Dort; Alnawaz Rehemtulla; Brian D Ross
Journal:  Mol Pharm       Date:  2010-10-27       Impact factor: 4.939

8.  PET imaging of brain astrocytoma with 1-11C-acetate.

Authors:  Ren-Shyan Liu; Cheng-Pei Chang; Lee-Shing Chu; Yum-Kung Chu; Hung-Jen Hsieh; Chi-Wei Chang; Bang-Hung Yang; Shan-Hui Yen; Min-Chao Huang; Su-Quin Liao; Shin-Hwa Yeh
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-01-11       Impact factor: 9.236

Review 9.  Imaging in neurooncology.

Authors:  Andreas H Jacobs; Lutz W Kracht; Axel Gossmann; Maria A Rüger; Anne V Thomas; Alexander Thiel; Karl Herholz
Journal:  NeuroRx       Date:  2005-04

10.  Dynamic contrast-enhanced MR imaging.

Authors:  A R Padhani
Journal:  Cancer Imaging       Date:  2000-10-11       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.